Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 6/20 | 0.54 |
| ▸ | SRC | P12931 | 5/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 6/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942725 | 0.94 | ADK (0.52) | ADKSRCABL1RETDAPK3 | |
| SCHEMBL29780875 | 0.90 | ADK (0.52) | ADKSRCABL1RETDAPK3 | |
| SCHEMBL16769982 | 0.90 | ADK (0.52) | ADKSRCABL1RETDAPK3 | |
| SCHEMBL25612068 | 0.89 | ADK (0.51) | ADKSRCRIPK2ABL1RET | |
| SCHEMBL16769692 | 0.85 | ADK (0.50) | ADKSRCRIPK2ABL1RET | |
| SCHEMBL25048704 | 0.84 | ADK (0.45) | ADKSRCRIPK2ABL1RET | |
| SCHEMBL28800796 | 0.84 | ADK (0.47) | ADKSRCABL1RETLCK | |
| SCHEMBL20351622 | 0.81 | ADK (0.56) | ADKSRCRIPK2ABL1RET | |
| SCHEMBL29484542 | 0.81 | ADK (0.54) | ADKSRCRIPK2ABL1RET | |
| SCHEMBL16236390 | 0.81 | ADK (0.54) | ADKSRCRIPK2ABL1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4223760-B1 | HETEROAROMATIC NMDA RECEPTOR MODULATOR AND USES THEREOF | NOVARTIS AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-20250034145-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| EP-4440703-A1 | HETEROCYCLIC COMPOUNDS AS GCN2 AND PERK KINASE INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118715223-A | Heterocyclic compounds as GCN2 and PERK kinase inhibitors | 德西费拉制药有限责任公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240199617-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| CN-112513047-B | Heteroaromatic NMDA receptor modulators and uses thereof | 诺华股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20190241573-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| EP-3487503-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-05-29 | — | — | EP | disclosed |
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3350185-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018015879-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018015879-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046738-A1 | TRIAZOLONE COMPOUNDS AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046738-A1 | TRIAZOLONE COMPOUNDS AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199617-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN3A, GRIN2A | ADK 953/4885SRC 1322/4885RIPK2 1103/4885 |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | ADK 315/4885SRC 512/4885RIPK2 500/4885 |
| US-20190241573-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | PSEN1, CPT1A, IRS1 | ADK 2534/4885SRC 501/4885RIPK2 314/4885 |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | ADK 557/4885SRC 1950/4885RIPK2 301/4885 |
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | ADK 1933/4885SRC 776/4885RIPK2 161/4885 |
| US-20250034145-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN3A, GRIN2A | ADK 953/4885SRC 1322/4885RIPK2 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.